【摘要】：卵巢癌是導(dǎo)致女性死亡的主要癌癥之一,死亡率在婦科癌癥中居高不下。聚ADP核糖聚合酶(PARP)抑制劑可靶向殺滅同源重組修復(fù)缺陷的腫瘤細(xì)胞,包括乳腺癌易感基因(BRCA)突變的癌細(xì)胞,這種機(jī)制被稱為協(xié)同致死效應(yīng)。目前已有3個(gè)PARP抑制劑被FDA批準(zhǔn)用于治療晚期BRCA突變的卵巢癌。本文旨在闡述PARP抑制劑治療卵巢癌的作用機(jī)制,并對(duì)已進(jìn)入臨床試驗(yàn)階段的PARP抑制劑進(jìn)行綜述,以期為開(kāi)發(fā)新的卵巢癌治療藥物提供參考。
[Abstract]:Ovarian cancer is one of the leading causes of death in women, and mortality is high in gynaecological cancers. Poly (ADP) ribosomal polymerase (PARP) inhibitors can target tumor cells with homologous recombination repair defects, including breast cancer cells with BRCA mutations, a mechanism known as synergistic lethal effect. Three PARP inhibitors have been approved by FDA for the treatment of advanced BRCA mutant ovarian cancer. The purpose of this article is to explain the mechanism of PARP inhibitors in the treatment of ovarian cancer and to review the PARP inhibitors which have entered the clinical trial stage in order to provide a reference for the development of new ovarian cancer therapy drugs.
【作者單位】： 廣西醫(yī)科大學(xué);軍事醫(yī)學(xué)科學(xué)院毒物藥物研究所 抗毒藥物與毒理學(xué)國(guó)家重點(diǎn)實(shí)驗(yàn)室;
【基金】：國(guó)家“重大新藥創(chuàng)制”科技重大專項(xiàng)資助項(xiàng)目(2016ZX09J16104-001)
【分類號(hào)】：R979.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 周天，

本文編號(hào)：2132838